Repurposing anti-CMV T cells to eliminate cancer cells
Repurposing anti-CMV T cells to eliminate cancer cells
Redirecting Anti-CMV T Cells to Fight Cancer: A New Approach in Cancer Research
Immunotherapy, which harnesses the body's own immune system to fight cancer, has greatly improved treatment options in recent years, but often causes serious side effects. This thesis of Anne van Wijngaarden describes the development and testing of a new approach that redirects immune cells against the common cytomegalovirus (CMV) to attack cancer cells instead. Because these immune cells are already present in the body, this approach is much simpler and less costly than existing methods like CAR-T therapy.
The key idea is that by directing existing anti-CMV immune cells toward cancer cells, we may be able to fight cancer effectively with much less side effects. Laboratory experiments and animal studies show that this strategy produces promising results against both solid tumors and blood cancers. Initial safety tests indicate that this approach appears to cause much less side effects than existing immunotherapies, likely because it harnesses a natural immune response.
The results demonstrate that this method has potential for future clinical application. Follow-up studies to investigate safety and effectiveness in patients are currently being prepared.